This clinical trial is a prospective, open label, single arm oncological phase I/II trial in
patients with hepatocellular carcinoma and WNT signaling alterations. The trial consists of
two parts: Part A is a phase I study investigating the safety of DKN-01 administered as mono-
as well as combination therapy with sorafenib in a 2 step dose escalation.Part B is a phase
II study to investigate the anti-tumor activity and safety of DKN-01 in patients with
advanced HCC. DKN-01 is administered at the recommend phase II dose (RP2D) for monotherapy
and at the recommend phase II dose for combination therapy established in Part A.